2 days ago
AbbVie's Phase 3 Study on Telisotuzumab Vedotin: A Potential Game-Changer in NSCLC Treatment
Abbvie ((ABBV)), Abbvie (($CC: announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a Phase 3 clinical study titled 'A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer'. The study aims to evaluate the efficacy and safety of telisotuzumab vedotin compared to docetaxel in treating non-squamous non-small cell lung cancer (NSCLC) in adults who have undergone prior treatment.
The study tests two interventions: telisotuzumab vedotin, an investigational biological drug administered intravenously every two weeks, and docetaxel, an active comparator drug given intravenously every three weeks. The goal is to determine which treatment better reduces disease activity and manages adverse events.
This interventional study employs a randomized, parallel assignment model without masking, focusing primarily on treatment. Participants are randomly assigned to receive either telisotuzumab vedotin or docetaxel, with approximately 698 participants expected to be enrolled globally.
The study began on March 25, 2022, with primary completion and estimated completion dates yet to be announced. The latest update was submitted on July 22, 2025, indicating ongoing recruitment and study progress.
For investors, this study could significantly impact AbbVie's stock performance and investor sentiment, especially if telisotuzumab vedotin demonstrates superior efficacy and safety. Success in this trial could position AbbVie favorably against competitors in the NSCLC treatment market.
The study is ongoing, and further details are available on the ClinicalTrials portal.
